Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. trimmed its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 3.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,872,024 shares of the company's stock after selling 221,262 shares during the period. Baillie Gifford & Co. owned approximately 4.77% of Guardant Health worth $134,704,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of GH. ARK Investment Management LLC boosted its holdings in shares of Guardant Health by 233.5% in the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company's stock valued at $34,701,000 after acquiring an additional 1,059,104 shares during the period. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in Guardant Health during the 1st quarter worth $8,300,000. Bank of New York Mellon Corp grew its position in Guardant Health by 31.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,280,221 shares of the company's stock worth $36,973,000 after purchasing an additional 309,157 shares during the last quarter. Vanguard Group Inc. grew its position in Guardant Health by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 11,436,026 shares of the company's stock worth $235,925,000 after purchasing an additional 305,372 shares during the last quarter. Finally, Railway Pension Investments Ltd increased its stake in Guardant Health by 63.8% in the second quarter. Railway Pension Investments Ltd now owns 620,878 shares of the company's stock valued at $17,931,000 after purchasing an additional 241,800 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Price Performance

GH stock traded up $1.88 during midday trading on Wednesday, hitting $31.61. 2,929,414 shares of the stock were exchanged, compared to its average volume of 2,072,188. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $37.04. The stock's 50-day moving average price is $23.31 and its 200-day moving average price is $26.27.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company's quarterly revenue was up 33.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.73) EPS. As a group, research analysts forecast that Guardant Health, Inc. will post -3.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GH shares. TD Cowen raised their price target on Guardant Health from $41.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. Piper Sandler lifted their target price on Guardant Health from $30.00 to $34.00 and gave the company an "overweight" rating in a research note on Tuesday, August 13th. Leerink Partners dropped their target price on Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. The Goldman Sachs Group increased their price target on Guardant Health from $32.00 to $36.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $39.75.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.